Pular para o conteúdo principal
Ranking Invest

SLS - SELLAS Life Sciences Group, Inc.

Segmento: HealthcareSELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Análise Ranking Invest

Valor de Mercado
$ 2.05 Bi
IVR
0.02Índice proprietário de comparação relativa: 0,02.
IVR2
-0.06Leitura proprietária complementar: -6%.
MLL
-0.06Leitura proprietária complementar: -6%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 137.66 Mi

Dívida Líquida

-$ 138.34 Mi

L4T

-$ 32.46 Mi

Indicadores Básicos

ROE

-23.58%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

A0.14

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

C3.91

Margem

D0.00

Índices de Endividamento

DIV/PAT

-1.00

DIV/L4T

4.26

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.